Critical Outcome Technologies Inc. (COTI)

Critical Outcome Technologies Inc. (COTI)

September 18, 2009 09:00 ET

Critical Outcome Technologies Inc. Provides Business and Scientific Update at Annual General Meeting

LONDON, ONTARIO--(Marketwire - Sept. 18, 2009) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT), announced today that its Chief Executive Officer, Mr. Michael Cloutier, and President and Chief Scientific Officer, Dr. Wayne Danter provided a business and scientific update concerning the Company at its Annual General and Special Meeting (AGM) of Shareholders held on Thursday, September 10, 2009.

Highlights of the presentation included:

- a review of the Company's value proposition in the context of the current drug discovery and pre- clinical drug development industry;

- a brief summary of business accomplishments in the past three years;

- a summary of the development status of COTI's compound pipeline;

- a review of the positive preclinical test results for COTI-2, the Company's lead oncology drug compound and the development plan for COTI-2 going forward; and

- a general overview of financing and revenue initiatives in the next twelve months.

The full presentation can be found on COTI's website,

COTI also announced that at its AGM the shareholders approved an increase in the number of directors of the corporation from a minimum of three and maximum of ten to a minimum of three and a maximum of twelve. The shareholders also approved fixing the current complement of directors at nine and empowered the Board of Directors thereafter to determine from time to time the number of directors of the Corporation within the minimum and maximum limits.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. Currently, six targeted libraries of lead compounds are under active development; small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, adult acute leukemia, colorectal cancer and Alzheimer's disease.

For further information, please visit the website at

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information